7NS0 Stock Chart & Stats
€5.01
€0.00(0.00%)
At close: 4:00 PM EDT
€5.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.01 - €5.36
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€285.22M
Enterprise Value€234.29
Total Cash (Recent Filing)€132.63M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Aug 25, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding173,579,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.07Price Target Upside21.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage, Strong Equity BaseNear-zero debt and a sizable equity base provide durable financial flexibility to fund multi-quarter clinical programs and to absorb R&D volatility. This conservatism lowers near-term solvency risk and supports the firm’s ability to pursue partnerships or staged financing without immediate distress.
Focused Clinical-stage GI PipelineA clear, focused pipeline in oral GI therapeutics creates a durable strategic position: specialization concentrates R&D expertise, regulatory know-how, and trial design experience in a specific high-unmet-need area, improving odds of efficient development and targeted commercial positioning if trials succeed.
Partnership And Incremental FundingA development partnership that accelerates Phase 2 enrollment directly reduces timeline and execution risk for lead programs, while external equity investment signals third-party validation and modest runway extension. Together these structural supports help de-risk clinical development steps.
Bears Say
Minimal Revenue, Widening Operating LossesThe company remains pre-revenue with materially negative operating results, implying no internal profit engine to fund growth. Continued widening losses increase reliance on external capital, lengthen time to breakeven, and raise long-term execution risk absent a successful product launch or partnership monetization.
Persistent Cash BurnSustained negative operating and free cash flow indicate the business cannot self-fund development activities. Continued cash burn necessitates periodic financing rounds or licensing deals, which can be dilutive or restrictive; this structural funding need affects strategic optionality and long-term capital allocation.
Increased Authorized Shares Heighten Dilution RiskExpanding authorized shares and refreshed equity plans materially increase flexibility to raise capital or grant awards but also heighten long-term dilution risk for existing holders. This structural governance change makes future financing and compensation dilution more likely during ongoing clinical development.
Palisade Bio News
7NS0 FAQ
What was Palisade Bio, Inc.’s price range in the past 12 months?
Palisade Bio, Inc. lowest stock price was €5.01 and its highest was €5.36 in the past 12 months.
What is Palisade Bio, Inc.’s market cap?
Palisade Bio, Inc.’s market cap is €285.22M.
When is Palisade Bio, Inc.’s upcoming earnings report date?
Palisade Bio, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 17 days.
How were Palisade Bio, Inc.’s earnings last quarter?
Palisade Bio, Inc. released its earnings results on May 12, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of -€0.037 by -€0.006.
Is Palisade Bio, Inc. overvalued?
According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued.
Does Palisade Bio, Inc. pay dividends?
Palisade Bio, Inc. does not currently pay dividends.
What is Palisade Bio, Inc.’s EPS estimate?
Palisade Bio, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio, Inc. have?
Palisade Bio, Inc. has 173,579,670 shares outstanding.
What happened to Palisade Bio, Inc.’s price movement after its last earnings report?
Palisade Bio, Inc. reported an EPS of -€0.043 in its last earnings report, missing expectations of -€0.037. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Palisade Bio, Inc.?
Currently, no hedge funds are holding shares in DE:7NS0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.07 (21.19% Upside)
€6.07 (21.19% Upside)
Blogger Sentiment
Bullish
DE:7NS0 Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth €216.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1527.78%
Trailing 12-Months
Company Description
Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
7NS0 Stock 12 Month Forecast
Average Price Target
€6.07
▲(21.19% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―